Insight into the preclinical studies of phytomedicines in cancer theragnostics

Cancer is the second biggest cause of mortality and a significant public health issue. About 70% of low- and middle-income nations’ fatalities are attributed to cancer. It happens due to considerable DNA damage from therapeutic drugs, ionizing radiation, environmental toxins, and other factors. Cancer treatments, including chemotherapy, immunological therapy, targeted therapy, hormone therapy, radiation, and, have substantial drawbacks and potential adverse effects. In recent years, many plants have been given to cancer patients as an alternative medicine to prevent and cure cancer. These plants have significant. The main bioactive compounds responsible for chemoprotective and anticarcinogenic properties include polyphenols, flavonoids, alkaloids, saponins, triterpenes, tannins, and quinones are the main types of bioactive chemicals implicated in anticancer action. The primary activity of these compounds includes cell cycle arrest, suppression of angiogenesis, a decrease of cancer cell viability, and antiproliferative, cytotoxic, cytostatic, antimetastatic, apoptotic, and antioxidative effects. This review emphasizes the preclinical of phytomedicinal extracts as cancer theragnostic.